The prioritisation board, made up of senior members of NICE, drives our decision-making and maintains oversight of our guidance portfolio. It ensures the topics we select reflect national priorities ...

We estimate the NHS could potentially save £millions annually by greater use of the generic version of abiraterone rather than using enzalutamide and apalutamide, the other treatments we recommend at ...

Darolutamide, also known as Nubeqa and made by Bayer, is recommended in final draft guidance to treat adults with metastatic hormone-sensitive prostate cancer in combination with androgen deprivation ...

HEMA was convened to be an independent voice guiding best practices in international health technology assessment (HTA). It aims to critically examine and assess new methods, and is a collaboration ...

The pipeline of potential treatments is encouraging. Several medicines are in development. Others including GLP-1 agonists like semaglutide (currently used for obesity treatment) are being repurposed ...

There is a simple discount patient access scheme for garadacimab. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...

All NICE products on oesophageal cancer. Includes any guidance and quality standards.

Suggested remit: To appraise the clinical and cost effectiveness of lecanemab within its marketing authorisation for treating mild cognitive impairment or mild dementia caused by Alzheimer’s disease.

Suggested remit: To appraise the clinical and cost effectiveness of belantamab mafodotin within its marketing authorisation for treating relapsed or refractory multiple myeloma after 4 or more ...